Compare Travere Therapeutics Inc. Common Stock (TVTX) vs Utilities Select Sector SPDR Fund (XLU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Travere Therapeutics Inc. Common Stock vs Utilities Select Sector SPDR Fund — how do they compare? Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $4.88B), while Utilities Select Sector SPDR Fund trades at $41.93 (market cap $24.20B). The key difference: Utilities Select Sector SPDR Fund is far larger — about 5× Travere Therapeutics Inc. Common Stock's market cap, and Travere Therapeutics Inc. Common Stock is trading nearer its 52-week high, Utilities Select Sector SPDR Fund nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Travere Therapeutics Inc. Common Stock for 0 Days and Utilities Select Sector SPDR Fund for 81 Days on average.
| TVTX | XLU | |
|---|---|---|
Market Cap | $4.88B | $24.20B |
Volume | 1,668,577 | 27,226,247 |
Sector | Health | — |
52-Week High | $67.52 | $47.73 |
52-Week Low | $26.79 | $39.25 |
Typical Hold Time | 0 Days | 81 Days |
Enterprise Value | $5.01B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
XLU trades at $41.87, up 0.58% on the day, but remains under pressure after hitting recent 52-week lows near $39.13. Technical indicators show mixed signals with a bullish moving average trend but bearish oscillators, including an overbought RSI. The utilities sector faces headwinds from rising interest rates and regulatory challenges, particularly affecting data-center demand growth.
The outlook remains cautious as utility stocks face macro pressures from interest rates and regulatory uncertainty. While defensive characteristics provide some stability, near-term performance depends on interest rate direction and AI power demand evolution. Risk-reward appears balanced with potential for recovery if macro conditions stabilize.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →About Utilities Select Sector SPDR Fund
In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes securities of companies from the following industries: electric utilities; water utilities; multi-utilities; independent power and renewable electricity producers; and gas utilities. The fund is non-diversified.
Read more on XLU →
